Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
ProKidney (PROK) Stock Price & Analysis
75 Followers
PROK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $13.51
Previous Close$2.04
Volume783.63K
Average Volume (3M)663.24K
Market Cap
$551.81M
Enterprise Value$1.68B
Total Cash (Recent Filing)$362.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-3.6
Beta0.67
Next Earnings
May 09, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding229,343,531
10 Day Avg. Volume1,472,411
30 Day Avg. Volume663,243
Standard Deviation0.21
R-Squared0.11
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.41
Forecast
1Y Price Target
$4.50Price Target Upside120.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
ProKidney News
PremiumCompany Announcements
ProKidney Bolsters Leadership with Expert EVP, Enhances Operations
PremiumCompany Announcements
ProKidney Approves New Equity Incentives to Retain Key Staff
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommends a Buy Rating and $6 price target based on the company's upcoming interim results and pivotal studies.
Clinical Study ProgressThe change in enrollment criteria for the ongoing PROACT 1 Phase 3 clinical study is viewed positively as it may show a greater improvement in patients with advanced stage chronic kidney disease.
Drug EfficacyPROK's alignment with RMCL-002 study results and clinical feedback should enhance the focus on patients with higher risk of kidney failure, potentially improving the drug's efficacy.
Bears Say
Market ReactionPROK experienced a significant share price drop following competitor news.
Omission Of Critical DataCritical information such as the absolute impact on eGFR and time to delay in CKD progression with semaglutide treatment was not included in the press release.
Press Release ContentThe press release contained minimal details, and the relative risk reduction was on the lower range of expectations.
---
Ownership Overview
11.90% Insiders
10.66% Mutual Funds
16.97% Other Institutional Investors
60.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $1.12 and its highest was $13.51 in the past 12 months.
What is ProKidney’s market cap?
Currently, no data Available
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is May 09, 2024 which is in 14 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Mar 21, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.143 by $0.053.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -$0.35.
How many shares outstanding does ProKidney have?
ProKidney has 61,621,330 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.143. Following the earnings report the stock price went up 2.19%.
Which hedge fund is a major shareholder of ProKidney?
Among the largest hedge funds holding ProKidney’s share is Wexford Capital LP. It holds ProKidney’s shares valued at 22K.
---
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (120.59% Upside)
$4.50 (120.59% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 12.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.5%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.81%
Trailing 12-Months
Company Description
ProKidney
Social Capital Suvretta Holdings Corp III is a blank check company.
---
PROK Company Deck
---
PROK Earnings Call
Q3 2023
0:00 / 0:00
---
PROK Stock 12 Months Forecast
Average Price Target
$4.50
▲(120.59% Upside)
Technical Analysis
Best Analysts Covering PROK
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-14.42%
reiterated a buy rating last month
Copying Justin Zelin's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -14.42% per trade.
---